Recent

% | $
Quotes you view appear here for quick access.

Apricus Biosciences, Inc. Message Board

  • mecosmo2 mecosmo2 Jul 23, 2013 7:13 AM Flag

    Femprox

    • Femprox® Development Program: Femprox® is our lead product candidate for the treatment of female sexual arousal disorder, or FSAD. To date, we have completed seven clinical studies with Femprox® including a 100 patient Phase 2 study in the U.S. and a 400 patient Phase 3 study in China. The data generated from these studies strongly suggests that Femprox® has the potential to effectively treat FSAD in a female patient population where there are currently no available FDA approved treatment options. Moreover, we believe that Femprox® could be the first and only on-demand treatment approved for FSAD, where estimates of the market size are on par with that found in the erectile dysfunction market. The Company continues to advance the Femprox® development program in close consultation with our clinical and regulatory advisors. Our near-term goal is to seek confirmatory regulatory guidance from the U.S. FDA in the form of an End-of-Phase 2 meeting.

 
APRI
0.3451+0.0035(+1.02%)2:28 PMEDT